{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 50,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a bar chart to compare efficacy and provides a strategic rationale for pursuing both monomeric/trimeric and trimeric-only approaches.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/31",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.48,
        "x": 0.48,
        "y": 0.46
      },
      "kind": "callout",
      "text": "Spyre is advancing both monomeric/trimeric and trimeric-only TL1A mAbs to DC selection. Redundancy provides highest probability of creating a best-in-class therapeutic.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1316f6dd-0516-4cd3-bc56-ba9ca17cb8ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.4,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": "UC clinical remission rates Pbo-adjusted %",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3de85ff2-b2c4-446b-b48c-8ce261b8d347",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.48,
        "x": 0.48,
        "y": 0.22
      },
      "kind": "list",
      "text": "While PRA023 performed numerically better in a cross-trial comparison, it has yet to be determined whether monomeric/trimeric blockade is superior. Known biology suggests only trimeric blockade is necessary for effect.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea678a00-30a5-4bdc-b032-6667debfc5da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Figure sources: Prometheus PRA023 P2 ARTEMIS-UC data release, December 7, 2022. Roivant RVT-3101 Release Deck, January 4, 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a532836e-f8d5-4a6f-b820-5c1b1ada4a00",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.75,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Spyre is evaluating both trimeric and monomeric/trimeric TL1A blockade for SPY002",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97614996-243c-406f-aedb-dbf8c4cc253c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "4ee32269-209f-4152-af72-9012dbb2803c",
      "evidence": "The slide uses a chart/bar-vertical to compare UC clinical remission rates, which helps in selecting the right chart type for the data.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}